Wegovy Results and Reviews: What the Clinical Evidence Shows

What the trial results actually tell you, and what they don't

The STEP 1 trial is the bedrock of what we know about Wegovy's effectiveness. In 68 weeks, adults taking semaglutide 2.4 mg lost an average of roughly 15% of body weight compared with about 2.4% in the placebo group, a result that led NICE to recommend it for use within specialist weight-management services. You can read the full paper on the NEJM website.

But averages conceal a wide range. Some participants in the trial lost considerably more than 15%; others lost less. That spread exists because weight biology is personal. Factors including starting BMI, metabolic history, how well someone tolerates dose escalation, and the consistency of lifestyle changes alongside the medicine all affect where any individual lands.

The practical checking habit worth building: once a month, weigh yourself on the same scales at the same time of day and log it. A single weigh-in tells you very little; a four-week trend tells you something your prescriber can act on. If the number isn't moving after six months at the highest dose you can tolerate, NICE guidance is clear that continuing should be reviewed. That threshold exists to protect you, not to penalise you.

Reviews from real users reflect this same spread, and if you want to see what that variation looks like in practice, Wegovy reviews covering the before and after at the one-month mark give a grounded picture of where people typically are at that early stage. Those who found it harder frequently mention GI side effects in the earlier weeks of titration, which is consistent with the trial data: nausea, constipation and indigestion are the most commonly reported effects, and they tend to settle as the body adjusts.

The difference between 2.4 mg and the newer 7.2 mg results

Until April 2026, 2.4 mg was the highest available Wegovy dose. The MHRA's approval of a dedicated 7.2 mg single-dose pen on 14 April 2026 changed that picture materially. Trials at the higher dose reported average weight loss of around 20.7% over 72 weeks, which closes much of the gap previously seen between semaglutide and tirzepatide at its highest dose.

For anyone researching Wegovy reviews and results from before early 2026, it is worth knowing those accounts almost certainly describe the 2.4 mg experience. The 7.2 mg pen is a separate, newer option. Whether that higher dose is appropriate for you is a clinical decision made with a prescriber; no single dose suits every patient, and the titration schedule still starts low. You can read about Wegovy's results profile in more detail on our dedicated page.

The MHRA approved the 7.2 mg pen specifically for adults with a BMI of 30 or above for weight management. The cardiovascular indication and the recently approved MASH (fatty liver disease) indication are separate; they use different criteria and are outside the scope of weight-management prescribing.

What reviews don't usually mention, and why that matters

User reviews, wherever you find them, tend to describe the medicine in isolation. They rarely mention that semaglutide is titrated slowly for a reason, or that the appetite-suppression effect is not instant, it builds over weeks as the dose increases. Reviews written at one month often read very differently from those written at six months on the same treatment.

They also rarely mention what stopping looks like. Wegovy is a long-term intervention; weight can return after discontinuation, which is why NICE's two-year maximum for NHS use and the ongoing clinical reviews built into private prescribing matter. If you are weighing up the cost of Wegovy against expected results, the time horizon is worth factoring in.

Side effects that appear in reviews but sometimes get downplayed: nausea tends to be most noticeable in the first few weeks after starting or after a dose increase, and most people find it eases. Constipation can be underestimated, staying well hydrated and eating adequate fibre genuinely helps. Serious but rare side effects, including acute pancreatitis, are flagged in NHS safety guidance; seek urgent medical attention for severe abdominal pain that radiates to the back.

For a visual sense of what the results trajectory looks like across the first weeks and months, our pages on before-and-after accounts and early one-week results put the timeline into concrete terms.

How clinical assessment changes the results picture

One thing missing from almost every review is the prescriber's role in shaping the outcome. Titrating too fast increases the chance of side effects that force a pause or a step back. Titrating appropriately (and reviewing whether to continue based on how weight is actually moving) is the difference between an experience that reflects the trial data and one that does not.

NICE's published guidance on semaglutide (TA875) specifies that treatment should be used within a clinical framework that includes multidisciplinary support, not as a standalone prescription. That framework is what makes the averages in the trial achievable in practice.

At nume, every repeat order is reviewed by a GPhC-registered prescriber before it is dispensed, not auto-renewed, not rubber-stamped. If you have questions about what the results evidence means for your situation, our clinical team is there to work through it. For a broader look at what Wegovy involves before you decide anything, the Wegovy treatment overview covers the full picture. And if you are curious how it compares with other options available in the UK, the weight-loss treatments overview sets them side by side.

When you are ready to find out whether treatment is clinically suitable for you, start your free consultation with our prescribers.